Top 10 Medical Device R&D Budgets

We at FierceMedicalDevices present our compilation of the top 10 device companies and their R&D spending levels and priorities for 2011. Considered together, the data offers a telling story: In the face of a sluggish economy barely recovering from its historic collapse in 2008, almost all of the companies made a concerted effort to boost their R&D spending during their 2011 fiscal years.

Their message: It is crucial to invest in the future, no matter what the condition of the global economy.

While it is true that some pursued relatively modest R&D spending hikes, others were far more ambitious. But the trend is interesting when you consider that many pharmaceutical companies have focused on outsourcing their R&D to save money. What's more, the spending increases are all the more noteworthy for companies such as Medtronic ($MDT), which otherwise slashed jobs and reorganized in the face of sluggish sales.

Some companies viewed their R&D mandate as finding ways to improve and expand the use of existing products or update their technology. Others, such as GE Healthcare, engineered a concerted effort to tell the world their R&D spending is targeted toward big ideas (for example, developing next-generation molecular diagnostics to spot diseases such as Alzheimer's more quickly). Others, like Covidien ($COV), grew their R&D spending, in part, by default, after completing a shopping spree of new companies with promising device or medical instrument technologies.

Some R&D investment also went global. Covidien took this route in the fall by announcing plans for a Shanghai R&D center to develop medical device technologies and surgical tools for China and other emerging markets. It's not quite outsourcing in the traditional sense, but it does warrant closer watching. Johnson & Johnson ($JNJ) also took a similar route.

We hope this report is valuable to you. Thank you for reading and please follow us regularly on Twitter and at FierceMedicalDevices.com.

-- Mark Hollmer (email | Twitter) and Liz Jones Hollis (email | Twitter), editors-at-large

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.